had5-s-fusion+n-etsd vaccine
VaccineexperimentalCOVID-19
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 19, 2020 (NCT04591717)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04843722 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | ImmunityBio, Inc. |
| NCT04845191 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | ImmunityBio, Inc. |
| NCT04710303 | Phase 1 | Mar 2, 2021 | ImmunityBio, Inc. |
| NCT04732468 | Phase 1 | Feb 24, 2021 | ImmunityBio, Inc. |
| NCT06022224 | Phase 2/Phase 3 (Phase 3) | Dec 9, 2020 | ImmunityBio, Inc. |
| NCT04591717 | Phase 1 | Oct 19, 2020 | ImmunityBio, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunityBio, Inc. | For profit | 6 | 6 | 3 | 2020 |
1 organizations
Page 1 / 1